28 results on '"Cipolla, David"'
Search Results
2. Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.
3. Controlling the size and shape of liposomal ciprofloxacin nanocrystals by varying the lipid bilayer composition and drug to lipid ratio
4. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis
5. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species
6. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice
7. Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
8. Additional file 1 of Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
9. Inhaled nicotine replacement therapy
10. Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection.
11. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-a-accelerated lupus nephritis in mice.
12. Correction for Plaunt et al., “Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections”
13. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
14. An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells
15. Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery
16. Inhaled Medicines: Past, Present, and Future
17. Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties
18. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
19. Minimizing Variability of Cascade Impaction Measurements in Inhalers and Nebulizers
20. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
21. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
22. Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
23. Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin
24. Development, characterization and pulmonary disposition of liposomal ciprofloxacin formulations
25. Development of Liposomal Ciprofloxacin to Treat Lung Infections
26. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary MRSA Infections
27. Effective Treatment of Mycobacterium aviumsubsp. hominissuisand Mycobacterium abscessusSpecies Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin
28. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.